Amgen Analyst Ratings
Amgen Analyst Ratings
Research Alert: CFRA Adds Amgen Inc. To The High-quality Capital Appreciation Portfolio
Barclays Sticks to Its Hold Rating for Amgen (AMGN)
HSBC Adjusts Price Target on Amgen to $356 From $322
Redburn Adjusts Price Target on Amgen to $170 From $180, Keeps Sell Rating
Amgen Analyst Ratings
Redburn Atlantic Adjusts Price Target on Amgen to $180 From $170
Mizuho Securities Raises Amgen's Price Target to $235 From $223
Amgen Analyst Ratings
RBC Capital Reaffirms Their Buy Rating on Amgen (AMGN)
Morgan Stanley Adjusts Price Target on Amgen to $310 From $271, Keeps Equalweight Rating
Amgen Analyst Ratings
Amgen Analyst Ratings
Amgen Analyst Ratings
Amgen Analyst Ratings
Barclays Sticks to Their Sell Rating for Amgen (AMGN)
Amgen Analyst Ratings
Amgen Stock Downgraded Amid Obesity Drug Uncertainty
Oppenheimer Adjusts Amgen Price Target to $380 From $350, Maintains Outperform Rating